



**Sydney Cancer Conference 2018**  
**11 - 12 October 2018**  
**International Convention Centre, Sydney**



**Thursday 11 October 2018**

	Cockle Bay Room 1	Meeting Room C4.6	Meeting Room C4.7
<b>Session 1</b>	<b>Opening Ceremony and Plenary</b> <i>Chairs: A/Prof Roger Bourne and Dr Jenny Wang</i>		
09:00	Welcome to Country  Opening Address <b>Professor David Currow</b> <i>Cancer Institute NSW</i>		
09:15	The last decade in cancer research - where we were then and where we are now <b>Professor Sanchia Aranda</b> <i>Cancer Council Australia</i>		
09:45	Changing role of imaging in neuro-oncology <b>Professor Susan Chang</b> <i>University of California, San Francisco</i>		
10:30	Morning Tea		
<b>Session 2</b>	<b>Tumour microenvironment / stem cells</b> <i>Chair: Dr Jenny Wang</i>	<b>Clinical research</b> <i>Chair: A/Prof Viive Howell</i>	<b>Public health, quality of life and survivorship</b> <i>Chair: Prof Elizabeth Sullivan</i>
11:00	Endothelial niche regulation of normal and malignant haematopoietic stem cells <b>Professor Ingrid Winkler</b> <i>Translational Research Institute</i>	Engaging rural clinician in translational research: an exemplar in lung cancer <b>Dr Nicole Rankin</b> <i>Cancer Council NSW</i>	Cervical cancer elimination: When might it be achievable? <b>Professor Karen Canfell</b> <i>Cancer Council NSW</i>
11:30	115: Hepatic metastases from breast cancer: liver extracellular matrix controls growth, invasion and drug sensitivity <b>Anna Guller</b>	62: Mechanisms of balance impairment in cancer survivors with chemotherapy-induced peripheral neuropathy <b>J. Matt McCrary</b>	46: Survivorship care plans and cancer survivors' patient-reported outcomes: A meta-analysis <b>Rebecca E. Hill</b>
11:45	98: ROBO2 is a stroma suppressor gene in the pancreas through regulation of TGF-beta <b>Andreia Pinho</b>	73: Investigating chemotherapy induced peripheral neuropathy in cancer survivors: an online patient survey <b>Eva Battaglini</b>	140: 'I was in a dark place and now I feel alive': Process evaluation of a psychological intervention for melanoma patients <b>Fay HUANG</b>
12:00	116: A novel cancer stem cell-targeted therapy characterised in highly translatable xenograft models of acute leukaemia <b>Basit Salik</b>	84: Moving towards an interactive cancer shared care plan solution <b>Mark Harris</b>	57: Future burden of cancer in Australia attributable to current modifiable behaviours <b>Maarit A. Laaksonen</b>
12:15	110: Delta40p53 is associated with stem cell markers in breast cancer <b>Kelly Avery-Kiejda</b>	123: Optimising Dose via TDM: Mitotane as a Model for Implementation of Personalised Therapy <b>Stephen Ackland</b>	21: Public perceptions of thyroid cancer overdiagnosis, overtreatment and communication strategies: a qualitative study. <b>Caitlin Semsarian</b>
12:30	24: Understanding Fibroblast Activation Protein as a Molecular Target in Tumour Stroma Using Degradomics and Proteomics <b>Hui Emma Zhang</b>	7: Advanced cancer patient perspectives on consenting to molecular tumour profiling: A qualitative study <b>Megan Best</b>	78: Cognitive Difficulties for Women after Breast Cancer: Compounding Problems When Trying to Return to Work <b>Joanne Lewis</b>
12:35	37: A new strategy to reduce prostate cancer stem cells by combining of BBI and α-TOS <b>Saki Kaneko</b>	66: The Needs of Young People After Death of a Family Member to Cancer: Validating the Bereaved Cancer Needs Inventory <b>Richard Tindle</b>	47: Salivary gland tumours and mobile phone use: fact or fiction? <b>Keshini Vijayan</b>
12:40	Lunch and Poster Viewing		
<b>Session 3</b>	<i>Chairs: A/Prof Roger Bourne and Dr Jenny Wang</i>		
14:10	TNF in anti-tumour immunity and resistance to immunotherapy <b>Dr Jane Olliaro</b> <i>Peter MacCallum Cancer Centre</i>		
14:55	The survivorship experiences of Australian Aboriginal and Torres Strait Islander peoples with cancer <b>A/Professor Patricia Valery</b> <i>QIMR Berghofer</i>		
15:40	Cancer Survivor <b>Ms Cheryl Grant</b>		
16:00	Overview of translational research workshop agenda		
16:10	Afternoon Tea		
<b>Session 4</b>	<b>Translational Cancer Research Workshop</b> <i>Chair: A/Prof Kieran Scott</i>		
16:40	Big Data: "How will all these data help the cancer patient?" Workshop Panel <b>Panelists</b> - Ms Cheryl Grant - Ms Nadia Levin, <i>Research Australia</i> - Professor Tim Shaw, <i>The University of Sydney</i> - A/Prof Kristine Barlow-Stewart, <i>The University of Sydney</i> - A/Prof Winston Liauw, <i>South Eastern Sydney Local Health District</i>		
18:00 - 19:00	Conference Social Event and Poster Viewing		

\*Please note the program is current as of Monday 10 September and subject to change



**Sydney Cancer Conference 2018**  
**11 - 12 October 2018**  
 International Convention Centre, Sydney



**Friday, 12 October 2018**

	Cockle Bay Room 1	Meeting Room C4.6	
<b>Session 5</b>			
08:00		<p align="center"><b>Early Career Researcher &amp; Postgraduate Student Breakfast Session</b>          "Research as a career in the 21st century"</p> <p align="center"><b>Panelists</b>          Chair - Prof. Elizabeth Sullivan          - Prof. Susan Chang, <i>University of California, San Francisco</i>          - A/Prof Kellie Charles, <i>A/Prof in Pharmacology, School of Medical Sciences, University of Sydney</i>          - Professor Roger Reddel, <i>Kids Cancer Alliance (Director, Children's Medical Research Institute)</i></p> <p align="center"><b>Invited Guests</b>          - Prof. Michael Boyer, <i>Sydney Catalyst</i>          - Prof. Paul Harnett, <i>Sydney West</i>          - Prof. Alexander Engel, <i>Sydney Vital</i>          - Prof. Jennifer Byrne, <i>Kids Cancer Alliance</i>          - Assoc. Prof. Mark Harris, <i>TCRN</i>          - Prof. Paul De Souza, <i>CONCERT</i>          Prof. Stephen Ackland, <i>Hunter Cancer Research Alliance</i>          Tickets available at additional cost</p>	
<b>Session 6</b>			
09:00	<p>Overview of CINSW Translational Cancer Research Centres          Chairs: Dr Kimberly Docking and A/Prof Therese Becker  <b>Professor Paul De Souza, A/Professor Mark Harris, Professor Alexander Engel, Professor Michael Boyer, Professor Paul Harnett, Professor Jennifer Byrne Professor Steven Ackland</b></p>		
09:45	<p>Precision systems oncology: from leukemias to solid tumors  <b>Professor Olli P Kallioniemi</b>  <i>Karolinska Institute, Sweden and Institute for Molecular Medicine Finland, University of Helsinki</i>          Chair: Dr Kimberly Docking</p>		
09:45			
		Meeting Room C4.6	Meeting Room C4.7
10:30		Morning Tea	
<b>Session 7</b>		<i>Cancer biology</i> Chair: Dr Esther Lim	<i>Clinical biomarkers</i> Chair: Jessica Lee
11:00	<p>Steps towards a comprehensive survey of the proteomic landscape of human cancer  <b>Professor Roger Reddel</b>  <i>The University of Sydney</i></p>	<p>Blood based biomarkers for prognosis and monitoring of patients with melanoma  <b>Dr Elin Gray</b>  <i>Edith Cowan University</i></p>	<p>How many cancers might we prevent? Analyses of the preventable burden of cancer in Australia?  <b>Professor David Whiteman</b>  <i>QIMR Berghofer</i></p>
11:30	<p>19: Dietary sucrose intake increases liver tumour burden in a mouse model of diethylnitrosamine-induced liver cancer  <b>Ghazal Alipour</b></p>	<p>97: Nuclear IGFBP-3 is a potential biomarker for response to EGFR-sphingosine kinase targeted therapy in TNBC  <b>Janet Martin</b></p>	<p>145: Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia  <b>Mawar Karsa</b></p>
11:45	<p>88: Targeting NAD<sup>+</sup> biosynthesis as a therapeutic strategy for high-risk paediatric ALL  <b>Klaartje Somers</b></p>	<p>79: CD83 is a New Potential Biomarker and Therapeutic Target for Lymphoma  <b>Xinsheng Ju</b></p>	<p>109: Amiloride Provides Neuroprotection Against Preclinical Paclitaxel-Induced Peripheral Neuropathy  <b>Justin Lees</b></p>
12:00	<p>101: Targeting the aryl-hydrocarbon receptor (AhR) pathway to selectively kill breast cancer cells  <b>Jennette Sakoff</b></p>	<p>68: Sensitivity testing of CTCs to chemotherapeutic agents as a predictor of therapeutic response and clinical outcome  <b>Joachim Fluhrer</b></p>	<p>102: Can risk attitudes determine sun-exposure behaviours and modify a melanoma genomic risk intervention?  <b>Rachael Morton</b></p>
12:15	<p>108: Targeting a novel metabolic regulatory mechanism in acute myeloid leukaemia.  <b>Patrick Connerty</b></p>	<p>12: Polygenic breast cancer risk: A prospective study of uptake and outcomes among high-risk women  <b>Tatiane Yanes</b></p>	<p>6: The mammographic density of Indigenous women attending breast screening in the Northern Territory  <b>Kriscia Tapia</b></p>
12:30	<p>126: Targeting ABCE1 disables MYC-driven protein synthesis to block neuroblastoma progression  <b>Jixuan Gao</b></p>	<p>16: TMEM and Menacal: new prognostic markers for breast cancer  <b>Thomas Rohan</b></p>	<p>61: A genetic variant in telomerase gene modifies cancer risk in Lynch syndrome patients harbouring MSH2 mutations  <b>Bente Talseth-Palmer</b></p>
12:35	<p>72: Targeting adaptive metabolic reprogramming in pancreatic ductal adenocarcinoma to overcome chemotherapy resistance  <b>Sarah Hancock</b></p>	<p>45: Lymphoma in Border Collies: Survey results and genetic investigations  <b>Pamela Soh</b></p>	<p>23: Germline genomic analysis in childhood cancer patients suspected of genetic predisposition to cancer  <b>Dianne E. Sylvester</b></p>
12:40		Lunch and Poster viewing	
<b>Session 8</b>		<i>Cancer Immunology</i> Chairs: Ms Sherry Tu and Mr Abel Tan	<i>Imaging &amp; radiotherapy/ Bioinformatics</i> Chair: A/Prof Roger Bourne
14:00	<p>Emerging Advances in Cellular Therapies: Immune correlates to immune contexture  <b>Professor Rajiv Khanna</b>  <i>QIMR Berghofer</i></p>	<p>Targeted Radiotherapy: Current Trends and Future Directions  <b>Professor Paul Keall</b>  <i>The University of Sydney</i></p>	<p>Light and nanotechnology for probing and interacting with biological systems  <b>Professor Ewa Goldys</b>  <i>UNSW Australia</i></p>
14:30	<p>111: Circulating cytokines predict toxicity in melanoma patients receiving combination immunotherapy.  <b>Esther Lim</b></p>	<p>36: Heterogeneity in the single-cell signalling response promotes chemoresistance in neuroblastoma  <b>David Croucher</b></p>	<p>13: A modular strategy for the bioconjugation of nanoparticles in targeted cancer therapeutics  <b>Andrew Care</b></p>
14:45	<p>39: Microglial responses to syngeneic glioblastoma in a 18-KDA translocator protein (TSPO) knockout  <b>Manuel Graeber</b></p>	<p>9: Controlled drug release from a liposomal delivery platform triggered by X-ray radiation  <b>Wei Deng</b></p>	<p>80: Three-dimensional brain tumour models: a tool to advance the detection and treatment of Glioblastoma Multiforme  <b>Annemarie Nadort</b></p>
15:00	<p>33: Transient 'priming' by FAK inhibition improves sensitivity to standard-of-care in Pancreatic Ductal Adenocarcinoma  <b>Kendelle Murphy</b></p>	<p>146: The advantage of phase-contrast imaging in computed tomography of the breast  <b>Syedamir Tavakoli Taba</b></p>	<p>26: CADg: a novel mammographic computer-aided detection tool incorporating the gist of the abnormal  <b>Ziba Gandomkar</b></p>
15:15	<p>92: Overcoming Pgp-Mediated Drug-Resistance by Releasing Lysosomal Stored Doxorubicin with Lysosomal Targeting Agents  <b>Lionel Leck</b></p>	<p>91: Discovery of novel prognostic markers in triple-negative breast cancer by MALDI MS imaging  <b>Robert Baxter</b></p>	<p>11: Cracking the code of intra-tumour heterogeneity during carcinoma response to therapy using single cell technology  <b>Naisana Seyedasli</b></p>
15:30	<p>104: Expression of lncRNAs in ovarian cancer-associated fibroblasts is prognostic for patient survival  <b>Emily Colvin</b></p>	<p>127: Fifty shades of radiobiology: alpha/beta ratios exposed  <b>Ana Esteves</b></p>	<p>22: Australia's pilot trial of digital breast tomosynthesis (3Dmammography) population-based screening: Interim results  <b>Nehmat Houssami</b></p>
15:35	<p>70: Dual inhibition of JAK and Src: A novel and promising therapeutic combination for pancreatic cancer  <b>Ashleigh Parkin</b></p>	<p>103: False positive results and incidental findings with CT or PET/CT surveillance in stage III melanoma patients  <b>Rachael Morton</b></p>	<p>133: Liquid biopsies to detect clinical breast cancer biomarkers  <b>Sarah Jeffreys</b></p>
15:40		Afternoon Tea	
16:00	<p><i>Closing remarks and awards presentation</i>          Chairs: Dr Jenny Wang and A/Prof Roger Bourne</p>		

*\*Please note the program is current as of Wednesday 19 September and subject to change*